Ocugen, Inc. - OCGN
About Gravity Analytica
Recent News
- 03.05.2025 - Ocugen, Inc. Q4 and Full Year 2024 Financial Results and Business Highlights
- 03.05.2025 - Ocugen, Inc. Q4 and Full Year 2024 Financial Results and Business Highlights
- 03.05.2025 - Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results
- 03.05.2025 - Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results
- 03.05.2025 - Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results
- 03.03.2025 - Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease
- 03.03.2025 - Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease
- 03.03.2025 - Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease
- 02.27.2025 - Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease
- 02.27.2025 - Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease